Duchenne Muscular Dystrophy: Gene Therapy Deaths & Future Progress
Table of Contents
The Duchenne community,a resilient force forged in the crucible of a devastating rare disease,is issuing a fervent plea for continued progress and access to innovative therapies.In the wake of recent setbacks, including Sarepta Therapeutics’ notable layoffs and the FDA’s initial rejection of Capricor’s cell therapy, the community emphasizes that rolling back advancements would be a grave disservice to patients and a betrayal of years of hard-won advocacy.
The Hard-Won Battle for Access
For generations, families affected by Duchenne muscular dystrophy (DMD) have waged a relentless war against a disease that offers little hope. Their tireless efforts to educate researchers and regulators about the necessity of tolerating risk in the face of fatal conditions have yielded tangible results. Through persistent advocacy for fast-track designations, accelerated approvals, and robust drug coverage, families now have access to therapies that were once the stuff of dreams for previous generations.
“We’ve advocated as if lives depend on it,” state Jennifer Handt, founder of Charlie’s Cure, and Kelly Maynard, founder of the Little Hercules Foundation, in a joint statement. ”As a result, families have access to therapies that previous generations affected by Duchenne could only dream of.”
A call Against Regressive Measures
The authors caution against any moves that could curtail this hard-won progress. While acknowledging the emotional toll of setbacks, they argue that regressive measures-whether through regulatory restrictions or enabling insurance plans to deny access to approved therapies-will not bring back those lost to the disease or its treatments.
“We must avoid regressive measures that limit families’ choices,” they urge. Such actions, they warn, could also create a “catastrophic chilling affect,” discouraging biotechs from undertaking the inherent risks of innovation. Instead, the focus must remain on collectively empowering every step forward.”Investment in science begets more options and, in turn, more science – and our children need all the science and options they can get.”
Hope Amidst FDA Scrutiny
The Duchenne community acknowledges the signals from new FDA leadership,suggesting a recognition of the power of choice and access for patients and families. However, they express concern over the FDA’s recent initial rejection of Capricor’s deramiocel for Duchenne cardiomyopathy, a critical area of unmet need given the disease’s ultimate lethality.
Despite this, a sense of hope persists. “We remain hopeful that future policies will accelerate solutions for dying patients and put decision-making in the hands of families, even when those decisions involve risk,” the authors state.They firmly believe that difficult discussions and decisions made collaboratively with doctors are always preferable to the alternative: no options at all.
Risk: A Privilege in Rare Disease
Ultimately, the authors posit that in the realm of rare diseases, “risk is a privilege.” The devastating loss of lives in the pursuit of treatment is a painful reality, but it is equally devastating to contemplate a return to a time when no therapeutic avenues existed.
“we must not forfeit our privilege of risk to knee-jerk wishes to remove risk from the equation entirely,” they implore. Rather, a collective effort is required from families, clinicians, policymakers, and industry to learn from both the triumphs and tragedies associated with new therapies. This shared learning, they contend, is crucial to sustaining and multiplying progress for the sake of patients who cannot afford to wait.Jennifer Handt is a writer, communications adviser, and founder of Charlie’s Cure, a nonprofit that funds key research to find a cure for Duchenne muscular dystrophy. Kelly Maynard is a rare disease advocacy leader and founder of the Little Hercules Foundation,a nonprofit dedicated to unlocking treatment access for families facing rare disease. Little Hercules has received grant funding from companies working on DMD, including Sarepta.